Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

MIRECC/CoE

Menu
Menu

Quick Links

Veterans Crisis Line Badge
My healthevet badge
EBenefits Badge
 

PRIME Care Study

prime care full logo red gif
The purpose of this study is to determine the effectiveness of providing depressed Veterans and their providers the results of pharmacogenetic (PGx) testing for psychotropic medications. The study focuses on whether and how patients and providers use genetic test results given to them at the time an antidepressant is to be initiated to treat Major Depressive Disorder (MDD) and whether use of the test results improves patient outcomes. MDD is one of the most common conditions associated with military service and combat exposure, increases suicide risk, and worsens the course of common medical conditions, making it a leading cause of disability and mortality. Validation of a PGx test to personalize the treatment of MDD represents an important opportunity to improve the healthcare of Veterans.  Veteran recruitment will take place at 19 different VA Sites.      

ClinicalTrials.gov ID: NCT03170362

 

Contact

David W. Oslin, M.D.
Principal Investigator
CPL Michael J Crescenz VA Medical Center
215-823-5894
dave.oslin@va.gov

Erin Ingram
Senior Research Coordinator
CPL Michael J Crescenz VA Medical Center
215-823-5800 Ext. 2895
Erin.Ingram@va.gov